PRESS INFORMATION BUREAU पत्र सूचना कार्यालय GOVERNMENT OF INDIA भारत सरकार

Economic Times, Delhi Friday 4th July 2014, Page: 6

Width: 5.78 cms, Height: 5.57 cms, a4, Ref: pmin.2014-07-04.24.55

📓 Glenmark's New Molecule **Enters Human Trials**

NEW DELHI Glenmark Pharmaceuticals on Thursday said its new molecule for potential treatment of autoimmune diseases is entering

human trials. Glenmark Pharmaceuticals SA, a wholly-owned Swiss subsidiary of Glenmark Pharmaceuticals, said GBR 830 - a novel monoclonal antibody - is entering human trials. Monoclonal antibodies are produced by a single clone of cells grown in culture to produce unlimited quantities of identical antibodies. They are used in diagnosis, therapy and biotechnology.

R 8.0